Auris Medical Holding AG (NASDAQ: EARS) Starts Presentation at 29th Annual ROTH Conference
Auris Medical (NASDAQ: EARS) is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The company is focused on the phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Meniere's disease and vestibular vertigo (AM-125) and early-stage research and development projects. The company was founded in 2003 and is headquartered in Zug, Switzerland. For more information, visit the company’s website at www.aurismedical.com. About NetworkNewsWire…







